Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1113

Shown on this page

Current sort

Live official records

Conditions: Calcaneus Fracture
Interventions: Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA), Open Reduction Internal Fixation (ORIF) only; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Orange, California • Atlanta, Georgia • Macon, Georgia + 13 more

Conditions: Ulcerative Colitis
Interventions: ABX464, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 1,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 72
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Sun City, Arizona + 58 more

Conditions: Skin-Picking, Trichotillomania (Hair-Pulling Disorder)
Interventions: Memantine, ComB Behavioral Therapy; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nicotine Use Disorder, Smoking Cessation, Smoking Cessation Intervention
Interventions: Enhanced Courage to Quit; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 26 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Stones, Urine Specimen Collection
Interventions: Apple Cider Vinegar; Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors
Interventions: BAY3375968, Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more

Conditions: Hepatectomy
Interventions: Methylprednisolone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 14 more

Conditions: Memory
Interventions: Different cognitive and memory demands during the memory experiment, Different electrical stimulation parameters during cognitive and memory demands; Behavioral · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 99,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2041
U.S. locations: 142
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more

Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 106
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Cholangiocarcinoma
Interventions: Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Santa Monica, California • Stanford, California • Westwood, Los Angeles, California + 14 more

About this University of Chicago Medicine institution page

What this page lists: ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Chicago Medicine

Filter and sort this campus

Live official records

Primary Subtalar Arthrodesis for Calcaneal Fractures

ABTECT - Maintenance

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors

Implementation of Tobacco Cessation Programming at Community Behavioral Health Sites

The Effect of Apple Cider Vinegar Supplementation on 24-hour Urine Chemistry in Adults

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

A Study of Methylprednisolone in People Having Liver Surgery

Basic Experimental Study of Hippocampal Memory Functions

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

About this University of Chicago Medicine institution page